phase readout
saveNCT06617429: Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS)
ACTIVE_NOT_RECRUITINGupdated 2d ago
community read0 votes
Sponsor: Ultragenyx Pharmaceutical Inc. Phase: PHASE3. Conditions: Angelman Syndrome
view source ↗
comments(0)
5-min edit window · permanent after that